Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Productmarketing’

Where do drug names come from? According to Octavia Spencer’s SNL character, the contacts in her cellphone

Drugmakers spend big money crafting the names of their new products. Specialists draw on the “personalities” of each letter of the alphabet—which is why we get so many Z’s and X’s—brainstorm dozens of candidates and run their ideas by the FDA for its all-important approval.

Bron: FiercePharma Meer lezen »

Marcom: jouw kansen binnen de veranderende beroepenmarkt

De samenleving verandert snel vanwege technologische ontwikkelingen, robotisering en bijvoorbeeld social media. Niemand kan precies voorspellen wat er gaat gebeuren, maar over een ding zijn de meeste mensen het eens: de aard van het werk binnen marketing en communicatie gaat de komende jaren snel veranderen.

Bron: Frankwatching.nl Meer lezen »

De productmanager 2.0 heeft een agile start-up mentaliteit nodig

Productmanager is zo’n titel die je vaak hoort maar die heel variabel en bedrijfs-afhankelijk ingevuld wordt. In de financiële dienstverlening is het doorgaans iemand die zorgt dat het dienstenpakket van zijn werkgever aansluit bij wat de klanten willen. Maar wat als het web steeds groter wordt en de klant steeds meer flexibiliteit eist?

Bron: PMLiVE Meer lezen »

Pfizer says its Sutent meets primary endpoint in Phase III trials for kidney cancer recurrence

US pharma giant Pfizer (NYSE: PFE) said late-stage trials for its Sutent (sunitinib) met its primary endpoint as a treatment for kidney cancer.

Bron: InPharm.com Meer lezen »

Gilead receives EU approval for combo hepatitis C treatment

Gilead Sciences (NASDAQ: GILD) has received a marketing authorisation approval from the European Commission for combination treatment Epclusa (sofosbuvir/velpatasvir) for patients with all genotypes of chronic hepatitis C.  

Bron: InPharm.com Meer lezen »

Nice backs two cancer drugs from Novartis

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer and skin cancer.The recommendation is part of the final approvals for five drugs to treat four different conditions to be funded by the NHS. The regulator has backed Novartis’ Zykadia (ceritinib) to treat non-small-cell lung cancer […]

Bron: InPharm.com Meer lezen »

Trial of AbbVie’s Rova-T disappoints at ASCO

A cancer drug licensed by AbbVie in a $5.8bn deal has failed to impress at this year’s ASCO conference, sending the company’s shares into decline.

Bron: PMLiVE Meer lezen »

AbbVie, Janssen’s Imbruvica gets European approval to teat CLL

AbbVie (NYSE: ABBV) on Tuesday said Imbruvica (ibrutinib) has secured European regulatory backing to treat chronic lymphocytic leukemia or CLL. This is the fifth indication for the drug in the EU, which is co-developed by Janssen and AbbVie.  

Bron: InPharm.com Meer lezen »

Allergan launches Crestor generic in the US

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the first company to launch a generic of the drug in the US. Crestor has consistently been one of the highest selling in the drugs in the US, but went off patent earlier this year.

Bron: InPharm.com Meer lezen »

Three AstraZeneca drugs recommended by EMA committee

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended several new drugs in its latest meeting, including three AstraZeneca drugs and a Lilly treatment for non-small cell lung cancer. The committee adopted a positive opinion recommending the marketing authorisation of lesinurad, in combination with a xanthine oxidase inhibitor (XOI), for hyperuricaemia, a […]

Bron: InPharm.com Meer lezen »

« Oudere artikelen |